Summary

Eligibility
for people ages 21-55 (full criteria)
Healthy Volunteers
healthy people welcome
Dates
study started
study ends around
Principal Investigator
by Ziva Cooper, PhD
Headshot of Ziva Cooper
Ziva Cooper

Description

Summary

The purpose of this research is to assess the impact of CBD on the effects of THC.

Official Title

Interactions Between Delta-9-THC and CBD: A Controlled Human Drug-administration Study Probing a Harm Reduction Strategy

Details

Some evidence indicates that cannabidiol (CBD), a non-intoxicating cannabis component, might mitigate certain effects of THC. This study will examine possible roles for CBD in modulating THC's adverse and analgesic effects.

Keywords

Abuse, Drug, Pain, Cannabis, THC, CBD, Substance-Related Disorders, Marijuana Abuse, Counterfeit Drugs, nabiximols, Dronabinol, CBD 20 mg, CBD 40 mg, CBD 80 mg

Eligibility

You can join if…

Open to people ages 21-55

  • Male or non-pregnant and non-lactating females aged 21-55 years
  • Report cannabis use 1-7 days per week over the month prior to screening
  • Not currently seeking treatment for their cannabis use
  • History of inhaled cannabis use
  • Have a Body Mass Index from 18.5 - 34 kg/m2
  • Able to perform all study procedures
  • Must be using a contraceptive (hormonal or barrier methods)

You CAN'T join if...

  • Meeting DSM-V criteria for severe Cannabis Use disorder (CUD) or any substance use disorder other than nicotine, caffeine, mild or moderate CUD
  • Evidence of severe psychiatric illness (e.g. mood or anxiety disorder with functional impairment or suicide risk, schizophrenia) judged by the study physician (and PI) to put the participant at greater risk of experiencing adverse events due to completion of study procedures, interfere with their ability to participate in the study, or their capacity to provide informed consent.
  • Report using other illicit drugs in the prior 4 weeks
  • Current pain
  • Pregnancy
  • Currently enrolled in another research protocol
  • Not using a contraceptive method (hormonal or barrier methods)
  • Insensitivity to the cold water stimulus of the Cold Pressor Test
  • Any disorders that might make cannabis administration hazardous as determined by evaluation physician after review of all medical assessments along with medical history.
  • Not able to speak and read English

Lead Scientist at UCLA

  • Ziva Cooper, PhD
    Dr. Ziva Cooper is a Professor and the Vice Chair for Research in the Department of Psychiatry and Biobehavioral Sciences at the UCLA David Geffen School of Medicine. She also serves as Director of the UCLA Center for Cannabis and Cannabinoids, a cross-disciplinary hub for research and education, spanning preclinical, clinical, public health, and policy domains. Dr. Cooper received her B.S.

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, Los Angeles
Links
Sign up for this study
ID
NCT06859710
Phase
Phase 1 research study
Study Type
Interventional
Participants
Expecting 30 study participants
Last Updated